Company news

Inhibrx Biosciences, Inc. news in 2026

Inhibrx Biosciences, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Inhibrx Announces Participation in Upcoming Scientific Conferences

October 13, 2026

Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study

September 8, 2026

Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study

September 4, 2026

Inhibrx Reports Second Quarter 2026 Financial Results

August 13, 2026

Inhibrx Biosciences Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million

July 16, 2026

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma

June 15, 2026

Inhibrx Reports First Quarter 2026 Financial Results

May 14, 2026

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy

May 11, 2026

Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC

May 8, 2026

Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

April 21, 2026

Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

April 20, 2026

Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results

March 19, 2026

Inhibrx Announces Participation in Upcoming Scientific Conference

March 2, 2026

Decks in 2026